These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 107356)

  • 61. [Heparin and urokinase interactions in the fibrinolytic system].
    Villaverde CA; Badimón L; Badimón JJ; Valdecasas FG
    Arch Farmacol Toxicol; 1979 Dec; 5(3):268-9. PubMed ID: 397804
    [No Abstract]   [Full Text] [Related]  

  • 62. [Studies on the fibrinolytic therapy in patients with various renal diseases. Clinical effects of urokinase (author's transl)].
    Takasaki H; Shibata M
    Nihon Jinzo Gakkai Shi; 1981 Sep; 23(9):1271-80. PubMed ID: 7035725
    [No Abstract]   [Full Text] [Related]  

  • 63. Intravesical therapy of noninvasive bladder tumors (stage Ta) with doxorubicin and urokinase.
    Lundbeck F; Mogensen P; Jeppesen N
    J Urol; 1983 Dec; 130(6):1087-9. PubMed ID: 6644887
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prophylactic effect of triethylenethiophosphoramide on the recurrence rate of superficial bladder tumors.
    Mukamel E; Zitron S; Nissenkorn I; Servadio C
    Isr J Med Sci; 1980; 16(9-10):714-6. PubMed ID: 6776072
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Conversion of proteolytically modified form (Lys-form) of human plasminogen to plasmin by urokinase in the presence of tranexamic acid.
    Takada A; Takada Y
    Thromb Res; 1981 Aug 15-Sep 1; 23(4-5):411-9. PubMed ID: 6459659
    [No Abstract]   [Full Text] [Related]  

  • 66. Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis, and the effect of natural proteinase inhibitors and omega-aminocarboxylic acids.
    Thorsen S
    Dan Med Bull; 1977 Oct; 24(5):189-206. PubMed ID: 908205
    [No Abstract]   [Full Text] [Related]  

  • 67. Estimation of cell damage in monolayer culture using 14C-leucine incorporation.
    Kato T; Ishikawa K; Nemoto R
    Tohoku J Exp Med; 1977 Apr; 121(4):403-4. PubMed ID: 405755
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Studies on blood coagulation and fibrinolytic activities in the three cases of cerebral infarction treated with urokinase. 1st report--120,000 I.U. administrated-- (author's transl)].
    Fujita S; Itoga T; Shou T; Yamamoto H; Ishikawa H
    Rinsho Ketsueki; 1978 Jun; 19(6):850-8. PubMed ID: 713046
    [No Abstract]   [Full Text] [Related]  

  • 69. [A study of urokinase lysis time in patients with various renal diseases].
    Shimizu K; Kishi T; Ootaka M; Yamamoto J; Shibata M; Ban I; Sakai H; Kobayashi K
    Nihon Jinzo Gakkai Shi; 1982 Nov; 24(11):1233-41. PubMed ID: 6762457
    [No Abstract]   [Full Text] [Related]  

  • 70. Proceedings: Fibrinolysis versus fibrinogenolysis: the specificity of human vascular activator (VA) as compared to urokinase (UK) and streptokinase (SK).
    Lipinski B; Gurewich V; Hyde E
    Thromb Diath Haemorrh; 1975 Sep; 34(1):351. PubMed ID: 1188799
    [No Abstract]   [Full Text] [Related]  

  • 71. [Thio-tepa treatment for prevention of recurrence of surgically treated bladder tumors].
    Neagoe M
    Rev Chir Oncol Radiol O R L Oftalmol Stomatol Chir; 1980; 29(4):259-65. PubMed ID: 6457322
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A comparison of the abilities of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen.
    Miles LA; Greengard JS; Griffin JH
    Thromb Res; 1983 Feb; 29(4):407-17. PubMed ID: 6344314
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system.
    Mattsson C; Nyberg-Arrhenius V; Wallén P
    Thromb Res; 1981 Mar; 21(6):535-45. PubMed ID: 7022741
    [No Abstract]   [Full Text] [Related]  

  • 74. [Comparative effects of ancrod, urokinase and heparin on intraglomerular coagulation induced by progressive Masugi nephritis (author's transl)].
    Fujioka M
    Nihon Jinzo Gakkai Shi; 1980 Aug; 22(8):1113-24. PubMed ID: 7012408
    [No Abstract]   [Full Text] [Related]  

  • 75. Effect of urokinase upon euglobulin lysis time and thrombin time.
    Lee TK; Huang SC; Lin SA; Chien LM
    Taiwan Yi Xue Hui Za Zhi; 1976 Mar; 75(03):190-7. PubMed ID: 1066436
    [No Abstract]   [Full Text] [Related]  

  • 76. [Fibrinolytic treatment with urokinase of post acute phlebothromboses (author's transl)].
    Trübestein G; Brecht T; Etzel F
    Dtsch Med Wochenschr; 1979 Aug; 104(35):1241-2. PubMed ID: 477521
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Intravesical thio-tepa: a study of 3H-thymidine uptake in normal urothelium and FANFT-induced tumors in rats.
    Nieh PT; Daly JJ; Irwin RJ; Prout GR
    Invest Urol; 1979 May; 16(6):486-8. PubMed ID: 109416
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Thrombolytic treatment with urokinase (author's transl)].
    Tilsner V; Greul W
    MMW Munch Med Wochenschr; 1975 May; 117(20):865-8. PubMed ID: 124400
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Factor XIII cross-linking and the rate of fibrinolysis induced by streptokinase and urokinase.
    Rampling MW
    Thromb Res; 1978 Feb; 12(2):287-95. PubMed ID: 635844
    [No Abstract]   [Full Text] [Related]  

  • 80. Thrombin accelerating factor in various urokinase preparations.
    Takada A; Matsuda H; Urano T; Takada Y
    Thromb Res; 1979; 14(4-5):673-8. PubMed ID: 483262
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.